ES2384707T3 - Antibióticos entrecruzados de glucopéptidos y cefalosporinas - Google Patents

Antibióticos entrecruzados de glucopéptidos y cefalosporinas Download PDF

Info

Publication number
ES2384707T3
ES2384707T3 ES03755467T ES03755467T ES2384707T3 ES 2384707 T3 ES2384707 T3 ES 2384707T3 ES 03755467 T ES03755467 T ES 03755467T ES 03755467 T ES03755467 T ES 03755467T ES 2384707 T3 ES2384707 T3 ES 2384707T3
Authority
ES
Spain
Prior art keywords
group
ch2ch2
ch2ch2ch2
hydrogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03755467T
Other languages
English (en)
Spanish (es)
Inventor
Daniel Marquess
Martin S. Linsell
Derek S. Turner
Sean G. Trapp
Daniel D. Long
Paul Fatheree
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ES2384707T3 publication Critical patent/ES2384707T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ES03755467T 2002-05-24 2003-05-23 Antibióticos entrecruzados de glucopéptidos y cefalosporinas Expired - Lifetime ES2384707T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38327402P 2002-05-24 2002-05-24
US383274P 2002-05-24
PCT/US2003/016375 WO2003099858A1 (en) 2002-05-24 2003-05-23 Cross-linked glycopeptide-cephalosporin antibiotics

Publications (1)

Publication Number Publication Date
ES2384707T3 true ES2384707T3 (es) 2012-07-11

Family

ID=29584538

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03755467T Expired - Lifetime ES2384707T3 (es) 2002-05-24 2003-05-23 Antibióticos entrecruzados de glucopéptidos y cefalosporinas

Country Status (8)

Country Link
US (4) US6878686B2 (https=)
EP (1) EP1507796B1 (https=)
JP (2) JP4347799B2 (https=)
AT (1) ATE556088T1 (https=)
AU (1) AU2003231833A1 (https=)
ES (1) ES2384707T3 (https=)
TW (1) TWI325323B (https=)
WO (1) WO2003099858A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1140993E (pt) * 1998-12-23 2003-10-31 Theravance Inc Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
TWI325323B (en) * 2002-05-24 2010-06-01 Theravance Inc Cross-linked glycopeptide-cephalosporin antibiotics
JP2007500222A (ja) 2003-05-23 2007-01-11 セラヴァンス インコーポレーテッド 架橋グリコペプチド−セファロスポリン抗生物質
DE602004012269T2 (de) * 2003-07-11 2009-04-30 Theravance, Inc., South San Francisco Quervernetzte glycopeptid-cephalosporin-antibiotika
US20080020961A1 (en) * 2006-07-21 2008-01-24 Rodrigues Klin A Low Molecular Weight Graft Copolymers
EP2435464B1 (en) * 2009-05-29 2014-07-16 Covalx AG Cross-linking reagents for molecular interaction analysis
WO2012129493A1 (en) * 2011-03-24 2012-09-27 Seachaid Pharmaceuticals, Inc. Vancomycin derivatives
MX352760B (es) 2011-09-09 2017-12-07 Merck Sharp & Dohme Corp Star Metodos para tratar infecciones intrapulmonares.
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
EP2970164B1 (en) 2013-03-13 2017-05-03 Theravance Biopharma Antibiotics IP, LLC Crystalline form of a substituted thiazolylacetic acid triethylamine salt
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
DK2893929T3 (da) 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
KR102237887B1 (ko) 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693A (en) 1848-08-01 Window-catch
US7A (en) 1836-08-10 Thomas Blanchard Machine for boring holes and cutting lanyard-scores in deadeyes
US947926A (en) * 1908-09-15 1910-02-01 William C Meyer Expansion-reamer.
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
JPS6041682A (ja) 1983-08-16 1985-03-05 Meiji Seika Kaisha Ltd 新規セフアロスポリン化合物及びその製造法
US4921851A (en) 1986-06-09 1990-05-01 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
US5693791A (en) 1995-04-11 1997-12-02 Truett; William L. Antibiotics and process for preparation
CA2318394A1 (en) 1998-02-20 1999-08-26 Advanced Medicine, Inc. Novel antibacterial agents
US6437119B1 (en) 1998-05-07 2002-08-20 William Lawrence Truett Compounds formed from two or three antibiotics and their processes of preparation
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US7208572B2 (en) * 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
PT1140993E (pt) 1998-12-23 2003-10-31 Theravance Inc Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
AU2001238020A1 (en) * 2000-02-04 2001-08-14 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US20030008812A1 (en) * 2001-02-02 2003-01-09 Christensen Burton G. Glycopeptide derivatives
TWI335332B (en) 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
TWI325323B (en) * 2002-05-24 2010-06-01 Theravance Inc Cross-linked glycopeptide-cephalosporin antibiotics
JP2007500222A (ja) 2003-05-23 2007-01-11 セラヴァンス インコーポレーテッド 架橋グリコペプチド−セファロスポリン抗生物質
US7127856B2 (en) * 2003-06-06 2006-10-31 Hans T. Hagen, Jr. Insulated stud panel and method of making such
DE602004012269T2 (de) 2003-07-11 2009-04-30 Theravance, Inc., South San Francisco Quervernetzte glycopeptid-cephalosporin-antibiotika

Also Published As

Publication number Publication date
US20060025332A1 (en) 2006-02-02
US6995138B2 (en) 2006-02-07
ATE556088T1 (de) 2012-05-15
US6878686B2 (en) 2005-04-12
US20050209132A1 (en) 2005-09-22
AU2003231833A1 (en) 2003-12-12
US8084417B2 (en) 2011-12-27
JP2009256358A (ja) 2009-11-05
EP1507796B1 (en) 2012-05-02
TWI325323B (en) 2010-06-01
TW200307556A (en) 2003-12-16
US20040033939A1 (en) 2004-02-19
EP1507796A1 (en) 2005-02-23
US20090137460A1 (en) 2009-05-28
JP2006503805A (ja) 2006-02-02
US7405199B2 (en) 2008-07-29
JP4347799B2 (ja) 2009-10-21
WO2003099858A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
ES2384707T3 (es) Antibióticos entrecruzados de glucopéptidos y cefalosporinas
US8557978B2 (en) Cross-linked glycopeptide-cephalosporin antibiotics
ES2302034T3 (es) Antibioticos de cefalosporina-glicopeptido reticulados.
ES2335013T3 (es) Antibioticos de glucopeptido-cefalosporina reticulados.